+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

A comparison study of multiple measures of adherence to HIV protease inhibitors

A comparison study of multiple measures of adherence to HIV protease inhibitors

Annals of Internal Medicine 134(10): 968-977

A longitudinal cohort study was conducted to examine the relationship among a composite score of adherence, the 3 primary measures of adherence, and HIV virologic response in 108 HIV-infected adults receiving protease inhibitors or non-nucleoside reverse transcriptase inhibitors, monitored for 666 monthly intervals. Medication Event Monitoring System (MEMS), pill count, and interview combined into a composite adherence score (CAS), and HIV viral load were measured.

(PDF same-day service: $19.90)

Accession: 003342170

Download citation: RISBibTeXText

PMID: 11352698

DOI: 10.7326/0003-4819-134-10-200105150-00011

Related references

A comparison study of multiple measures of adherence to antipsychotic medication in first-episode psychosis. Journal of Clinical Psychopharmacology 30(1): 64-67, 2010

Correlation between repeated measures of plasma concentrations of protease inhibitors, medication adherence, and virologic outcome in HIV-infected patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 42: 272, 2002

Proteochemometric modeling of drug resistance over the mutational space for multiple HIV protease variants and multiple protease inhibitors. Journal of Chemical Information and Modeling 49(5): 1202-1210, 2009

Synthetic protease inhibitors inhibit candida albicans extracellular acid protease activity and adherence to endothelial cells. Abstracts of the Annual Meeting of the American Society for Microbiology 90: 425, 1990

Adherence to treatment with protease inhibitors and therapeutic outcome in an unselected cohort of HIV-infected patients: A retrospective study. Giornale Italiano di Malattie Infettive 6(3): 140-143, Maggio-Giugno, 2000

Comparison of azacyclic urea A-98881 as HIV-1 protease inhibitor with cage dimeric N-benzyl 4-(4-methoxyphenyl)-1,4-dihydropyridine as representative of a novel class of HIV-1 protease inhibitors: a molecular modeling study. Journal of Computer-Aided Molecular Design 13(3): 233-242, 1999

Adherence and preexisting major protease inhibitor resistance mutations are associated with virologic failure of a dual-class antiretroviral regimen with inhibitors of HIV-1 viral protease and integrase. Journal of the International Association of Physicians in Aids Care 11(1): 34-39, 2014

Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. Journal of Acquired Immune Deficiency Syndromes 36(5): 1100-1102, 2004

Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. Journal of Acquired Immune Deficiency Syndromes 30(3): 324-334, 2002

Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence. HIV Clinical Trials 5(5): 278-287, 2004

Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)--a randomized controlled trial of therapeutic drug monitoring and adherence support. Journal of Acquired Immune Deficiency Syndromes 41(4): 461-467, 2006

Adherence to protease inhibitors. Annals of Internal Medicine 134(7): 625-625, 2001

Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: Study on combinations of two kinds of HIV-1 protease inhibitors. Journal of Pharmacy & Pharmacology 52(10): 1239-1246, October, 2000